The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...

Bumpus replaced agency veteran Janet Woodcock as principal deputy commissioner in February 2024. She was previously the FDA’s ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...